16 results
8-K
EX-4.1
NKGN
NKGen Biotech Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-4.2
NKGN
NKGen Biotech Inc
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
NKGN
NKGen Biotech Inc
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.2
NKGN
NKGen Biotech Inc
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-4.1
ax08 oeju82bo0
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-4.1
1mgamau
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-4.2
0q24janfwqnyiea5
5 Oct 23
Index to Financial Statements
5:12pm
425
EX-4.1
h7cd30u5m t03l35nck
19 Sep 23
Business combination disclosure
3:52pm
8-K
EX-4.1
clsza amn
19 Sep 23
Entry into a Material Definitive Agreement
3:51pm
10-K
EX-4.5
e42qhz3shvylqjn5
30 Mar 22
Annual report
9:27pm
8-K
EX-4.1
ovh1x zojqf
25 May 21
Graf Acquisition Corp. IV Announces Pricing of $150 Million Initial Public Offering
5:10pm
- Prev
- 1
- Next